plazinemdor (CAD-9303) / Novartis - LARVOL DELTA

Affinity-1: Study of CAD-9303 in Subjects With Schizophrenia (clinicaltrials.gov) - P1; N=103; Completed; Sponsor: Cadent Therapeutics; Recruiting ➔ Completed; Trial primary completion date: Dec 2021 ➔ Sep 2021

Biomarker • Clinical • Trial completion • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

[VIRTUAL] AFFINITY-1: Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Neurophysiological Biomarkers of CAD-9303 (NMDA PAM) (APA 2021) - "CAD-9303 is an NMDA PAM under development to treat the residual symptoms of schizophrenia. Single doses have been well tolerated and yielded dose proportional increases in exposure. Preliminary pharmaco-EEG data suggests evidence of target engagement based on increased delta power in the frontal lobes bilaterally."

Biomarker • Clinical • P1 data • PK/PD data • Cardiovascular • CNS Disorders • Dyspepsia • Insomnia • Psychiatry • Schizophrenia • Sleep Disorder

Affinity-1: Study of CAD-9303 in Subjects With Schizophrenia (clinicaltrials.gov) - P1; N=132; Recruiting; Sponsor: Cadent Therapeutics; Trial completion date: Jun 2021 ➔ Dec 2021; Trial primary completion date: Jun 2021 ➔ Dec 2021

Biomarker • Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Affinity-1: Study of CAD-9303 in Subjects With Schizophrenia (clinicaltrials.gov) - P1; N=132; Recruiting; Sponsor: Cadent Therapeutics; N=48 ➔ 132; Trial completion date: Aug 2020 ➔ Jun 2021; Trial primary completion date: Aug 2020 ➔ Jun 2021

Biomarker • Clinical • Enrollment change • Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Novartis snaps up neuro partner Cadent for $210M upfront with promise of up to $560M more (FierceBiotech) - "Novartis will acquire all of Cadent’s outstanding stock in exchange for the upfront fee and up to $560 million in milestone payments. The duo expects the deal to close in the first quarter of 2021. Under the deal, Novartis will buy out the milestones and royalties for the depression asset, MIJ821, which it is testing in a phase 2 study. It also picks up CAD-9303, a treatment for schizophrenia..."

M&A • CNS Disorders • Depression • Schizophrenia

Cadent Therapeutics closes $15 million final equity tranche of series B financing (Businesswire) - "The Company plans to allocate all proceeds to continue the development for its lead cognitive disorder asset, CAD-9303...for the treatment of the cognitive deficits and negative symptoms of schizophrenia."

Financing • CNS Disorders • Schizophrenia

Affinity-1: Study of CAD-9303 in Subjects With Schizophrenia (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Cadent Therapeutics

Biomarker • Clinical • New P1 trial